Abbreviations CCP = cyclic citrullinated protein; RA = rheumatoid arthritis.
In a recent article Catalán and colleagues [1] examined the expression of FcγRIIB in naïve, memory and plasmablast B cell subsets from peripheral blood of patients with rheumatoid arthritis (RA) and the results were correlated with levels of autoantibodies to cyclic citrullinated proteins (anti-CCP) detected in matching serum. Firstly, they observed reduced FcγRIIB expression in memory and plasmablast B cells from patients compared to the levels expressed on B cells from healthy controls. Secondly, the expression levels of FcγRIIB inversely correlated with the titre of anti-CCP antibodies in patients' serum. Indeed, RA patients with low autoantibody titres expressed higher levels of this receptor. Th irdly, they also report an increased frequency of CD86, usually up-regulated upon activation, on memory and naïve B cells [2] . Intriguingly, RA patients responding to adalimumab treatment display 'normalized' levels of CD86 only on memory B cells, but not on naïve B cells, and reduced expression of FcγRIIB only on naïve B cells, but not on memory B cells, and this was accompanied by unchanged levels of anti-CCP antibodies. Although these results are based on a relatively small group of patients, they could, if confi rmed, advocate the use of FcγRIIB expression coupled to anti-CCP responses as a predictive biomarker to monitor the early stage of disease and progression.
Human Fc receptors for IgG (FcγRI, FcγRIIA, FcγRIIC, FcγRIIIA, FcγRIIIB, FcγRIIB) exert diff erent functions and have diverse affi nities for the Fc fragment of IgG, and these receptors are diff erentially expressed by a variety of cells [3] . B cells, however, exclusively express FcγRIIB, an inhibitory receptor that binds IgG immune complexes and negatively regulates B cell receptor activation. FcγRIIB is able to suppress or block B cell receptor activation by transmitting inhibitory signals via its cytoplasmic immunoreceptor tyrosine-based inhibitory (ITIM) motif upon simultaneous engagement with the B cell receptor [3] . Th us, reduced levels of these regulatory proteins could result in a lower threshold for B cell activation and stronger activating signals following B cell receptor cross-linking.
Strong evidence supports the hypothesis that FcγRIIB and IgG immune complexes may play a central role in the regulation of humoral responses, and that the defects in this system could contribute to the development of autoimmunity. Th ere is evidence that FcγRIIB preferentially limits activation of high affi nity autoreactive B cells in the periphery [4] . Indeed, mice lacking the FcγRIIB receptor develop exacerbated autoimmunity compared to wild-type mice [5] . Furthermore, when the pathogenicity of human RA-associated autoantibodies was tested by passive transfer into mice defi cient for FcγRIIB, mice developed infl ammation and histological lesions consistent with arthritis, supporting a direct role for humoral Abstract Aberrant immune responses play a pivotal role in the processes that cause infl ammation and joint damage in patients with rheumatoid arthritis (RA). Polyclonal B cell activation and the production of autoantibodies are immunological hallmarks of the disease. However, controversy surrounds the pathogenicity of autoantibodies, mainly because not all patients are seropositive (10% of RA patients are seronegative), suggesting that they could be markers rather than makers of disease. Catalán and collaborators report that patients with RA display reduced expression of FcγRIIB on memory B cells and plasma cells, which inversely correlates with autoantibody levels. Considering that FcγRIIB stimulation down-regulates antibody production, this work strengthens the link between autoantibodies and pathogenicity.
immunity in the development of autoimmune arthritis [6] .
Th e link between the inhibitory FcγRIIB and the modula tion of B cell activity and humoral tolerance has also been translated into humans. Expression of FcγRIIB was found to be considerably decreased in memory B cells from patients with systemic lupus erythematosus compared to the levels detected in healthy controls. Th is directly correlated with decreased FcγRIIB-mediated suppression of B cell receptor-induced down-stream signal ling events [7] . Furthermore, several studies link FcγRIIB polymorphisms to increased susceptibility to systemic lupus erythematosus [8] and with joint damage in patients with RA [9] . However, although it seems a likely candidate, a direct role for inhibitory FcγRIIB in the pathogenesis of RA has not been demonstrated.
FcγRIIB is diff erentially expressed on healthy B cells, depending on the stage of B cell development and, since FcγRIIB helps to regulate B cell receptor-mediated stimulatory signals, it acts as a gatekeeper controlling B cell proliferation and maturation [10] . However, the results presented by Catalán and colleagues did not show any stringent relationship between B cell activation measured by CD86 expression and levels of FcγRIIB, indicating that the relationship between FcγRIIB expression and B cell activation, especially in the context of infl ammatory disease, requires further exploration. Th e results presented by Catalán and colleagues go some way to support the hypothesis that RA is associated with decreased negative feedback of humoral and eff ector immune responses. In addition, although not formally proven, it is tempting to speculate that the increased levels of CD86 expression on naïve B cells may be involved in and precede the down-regulation of FcγRIIB on memory B cells. Less clear is why in a less infl amed environment (that is, after anti-TNFα treatment) the expression of FcγRIIB is not recovered to similar levels to those detected in healthy individuals.
Defects in other inhibitory receptors have also been linked with RA pathogenesis, including reduced expression of CTLA-4 (cytotoxic T-lymphocyte antigen 4) in regulatory T cells from patients [11] . In the case of CTLA-4, reduced expression was also asso ciated with abnormal function, but it remains to be seen whether FcγRIIB-mediated signalling is fully functional in B cells from RA patients. Abnormal FcγRIIB function could go some way to explain the discrepancy between FcγRIIB expression and B cell activation as determined by CD86 expression.
Finally, if FcγRIIB truly acts as a late checkpoint at the level of class-switched B cells or antibody-producing plasmablasts/plasma cells, and considering that autoreactive B cells are generated during the process of affi nity maturation, then the relationship between FcγRIIB expression in autoantibody-mediated disease such as RA merits further exploration. Indeed, diff er en tial FcγRIIB expression may infl uence other B cell functions, including antigen presentation and cytokine production, involved in RA pathogenesis.
